Skip to main content
Erschienen in: Cellular Oncology 5/2019

30.05.2019 | Original Paper

Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway

verfasst von: Mahendra Seervi, S. Sumi, Aneesh Chandrasekharan, Abhay K. Sharma, T. R. SanthoshKumar

Erschienen in: Cellular Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Anastasis is newly discovered process by which cells recover from late-stage apoptosis upon removal of a death stimulus. Recent reports suggest that cells may recover, even after the initiation of mitochondrial outer-membrane permeabilization (MOMP) and caspase activation. Here, we specifically studied the reversibility of late-stage apoptosis in cervical (HeLa) and breast (MDA-MB-231) cancer cells in relation to the extent of MOMP (limited or widespread). In addition, we explored the molecular factors involved in the anastatic process.

Methods

The extent of MOMP was assessed using time lapse confocal microscopic imaging, considering mitochondrial cytochrome c-GFP release as a marker for MOMP. Anastatic cells were generated by specifically recovering late-stage apoptotic (annexin V/PI positive) cervical and breast cancer cells. Molecular signaling events involved in death reversal were assessed using LC-MS/MS and qRT-PCR. Targeted chemical inhibition and shRNA-based gene silencing studies were employed to explore the role of the nuclear export pathway in anastasis and increased oncogenicity.

Results

Time-lapse imaging of drug-treated Cyt-c-GFP expressing cancer cells revealed cell recovery despite widespread MOMP. A few recovered anastatic cells were noted and these were found to proliferate through a selection-type of survival. They showed increased drug-resistance, migration and invasive potential compared to non-anastatic cancer cells. Network analysis using 49 proteins uniquely expressed in anastatic cells indicated upregulation of nuclear export/import, redox and Ras signaling pathways in both HeLa and MDA-MB-231 anastatic cells, indicating common molecular mechanisms in different cell types. Inhibition of XPO1 significantly reduced the recovery of apoptotic cells and abrogated acquired oncogenic transformation in the anastatic cancer cells.

Conclusions

Our study indicates that cancer cells can revert from apoptosis even after the induction of widespread MOMP. We noted a significant role of the nuclear-export pathway in the anastatic process of cancer cells. Inhibition of anastasis through the nuclear export pathway may be a potential therapeutic strategy for targeting drug-resistance, metastasis and recurrence problems during cancer treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat A.R. Delbridge, L.J. Valente, A. Strasser, The role of the apoptotic machinery in tumor suppression. Cold Spring Harb. Perspect. Biol. 4, a008789 (2012)CrossRefPubMedPubMedCentral A.R. Delbridge, L.J. Valente, A. Strasser, The role of the apoptotic machinery in tumor suppression. Cold Spring Harb. Perspect. Biol. 4, a008789 (2012)CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat S. Baig, I. Seevasant, J. Mohamad, A. Mukheem, H.Z. Huri, T. Kamarul, Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis. 7, e2058 (2017)CrossRef S. Baig, I. Seevasant, J. Mohamad, A. Mukheem, H.Z. Huri, T. Kamarul, Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis. 7, e2058 (2017)CrossRef
3.
Zurück zum Zitat S. Gupta, G.E. Kass, E. Szegezdi, B. Joseph, The mitochondrial death pathway: A promising therapeutic target in diseases. J. Cell. Mol. Med. 13, 1004–1033 (2009)CrossRefPubMedPubMedCentral S. Gupta, G.E. Kass, E. Szegezdi, B. Joseph, The mitochondrial death pathway: A promising therapeutic target in diseases. J. Cell. Mol. Med. 13, 1004–1033 (2009)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat R. Khosravi-Far, Death receptor signals to the mitochondria. Canc Biol Ther 3, 1051–1057 (2004)CrossRef R. Khosravi-Far, Death receptor signals to the mitochondria. Canc Biol Ther 3, 1051–1057 (2004)CrossRef
6.
Zurück zum Zitat H.L. Tang, H.M. Tang, K.H. Mak, S. Hu, S.S. Wang, K. M. Wong, C. S. Wong, H.Y. Wu, H.T. Law, K. Liu, C.C. Talbo Jr, W.K. Lau, D. J. Montell, M.C. Fung, Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol. Biol. Cell 23, 2240–2252 (2012) H.L. Tang, H.M. Tang, K.H. Mak, S. Hu, S.S. Wang, K. M. Wong, C. S. Wong, H.Y. Wu, H.T. Law, K. Liu, C.C. Talbo Jr, W.K. Lau, D. J. Montell, M.C. Fung, Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol. Biol. Cell 23, 2240–2252 (2012)
7.
Zurück zum Zitat X. Liu, Y. He, F. Li, Q. Huang, T.A. Kato, R.P. Hall, C.Y. Li, Caspase-3 promotes genetic instability and carcinogenesis. Mol. Cell 58, 284–296 (2015)CrossRefPubMedPubMedCentral X. Liu, Y. He, F. Li, Q. Huang, T.A. Kato, R.P. Hall, C.Y. Li, Caspase-3 promotes genetic instability and carcinogenesis. Mol. Cell 58, 284–296 (2015)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat A.X. Ding, G. Sun, Y.G. Argaw, J.O. Wong, S. Easwaran, D.J. Montell, CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. Elife 5, e10936 (2016)CrossRefPubMedPubMedCentral A.X. Ding, G. Sun, Y.G. Argaw, J.O. Wong, S. Easwaran, D.J. Montell, CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. Elife 5, e10936 (2016)CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat G. Ichim, J. Lopez, S.U. Ahmed, N. Muthalagu, E. Giampazolias, M.E. Delgado, M. Haller, J.S. Riley, S.M. Mason, D. Athineos, M.J. Parsons, B. van de Kooij, L. Bouchier-Hayes, A.J. Chalmers, R.W. Rooswinkel, A. Oberst, K. Blyth, M. Rehm, D.J. Murphy, S.W.G. Tait, Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol. Cell 57, 860–872 (2015)CrossRefPubMedPubMedCentral G. Ichim, J. Lopez, S.U. Ahmed, N. Muthalagu, E. Giampazolias, M.E. Delgado, M. Haller, J.S. Riley, S.M. Mason, D. Athineos, M.J. Parsons, B. van de Kooij, L. Bouchier-Hayes, A.J. Chalmers, R.W. Rooswinkel, A. Oberst, K. Blyth, M. Rehm, D.J. Murphy, S.W.G. Tait, Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol. Cell 57, 860–872 (2015)CrossRefPubMedPubMedCentral
11.
12.
Zurück zum Zitat I. Vermes, C. Haanen, H. Steffens-Nakken, C. Reutellingsperger, A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184, 39–51 (1995)CrossRefPubMed I. Vermes, C. Haanen, H. Steffens-Nakken, C. Reutellingsperger, A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184, 39–51 (1995)CrossRefPubMed
13.
Zurück zum Zitat A.L. Hong, Y.Y. Tseng, G.S. Cowley, O. Jonas, J.H. Cheah, B.D. Kynnap, M.B. Doshi, C. Oh, S.C. Meyer, A.J. Church, S. Gill, C.M. Bielski, P. Keskula, A. Imamovic, S. Howell, G.V. Kryukov, P.A. Clemons, A. Tsherniak, F. Vazquez, B.D. Crompton, A.F. Shamji, C. Rodriguez-Galindo, K.A. Janeway, C.W.M. Roberts, K. Stegmaier, P. van Hummelen, M.J. Cima, R.S. Langer, L.A. Garraway, S.L. Schreiber, D.E. Root, W.C. Hahn, J.S. Boehm, Integrated genetic and pharmacologic interrogation of rare cancers. Nat. Commun. 7, 11987 (2016)CrossRefPubMedPubMedCentral A.L. Hong, Y.Y. Tseng, G.S. Cowley, O. Jonas, J.H. Cheah, B.D. Kynnap, M.B. Doshi, C. Oh, S.C. Meyer, A.J. Church, S. Gill, C.M. Bielski, P. Keskula, A. Imamovic, S. Howell, G.V. Kryukov, P.A. Clemons, A. Tsherniak, F. Vazquez, B.D. Crompton, A.F. Shamji, C. Rodriguez-Galindo, K.A. Janeway, C.W.M. Roberts, K. Stegmaier, P. van Hummelen, M.J. Cima, R.S. Langer, L.A. Garraway, S.L. Schreiber, D.E. Root, W.C. Hahn, J.S. Boehm, Integrated genetic and pharmacologic interrogation of rare cancers. Nat. Commun. 7, 11987 (2016)CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat M.R. Dalman, A. Deeter, G. Nimishakavi, Z.H. Duan, Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 13, S11 (2012)CrossRefPubMedPubMedCentral M.R. Dalman, A. Deeter, G. Nimishakavi, Z.H. Duan, Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 13, S11 (2012)CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat K. Raza, A. Mishra, A novel anticlustering filtering algorithm for the prediction of genes as a drug target. Am J Biomed Eng 2, 206–211 (2012)CrossRef K. Raza, A. Mishra, A novel anticlustering filtering algorithm for the prediction of genes as a drug target. Am J Biomed Eng 2, 206–211 (2012)CrossRef
16.
Zurück zum Zitat P.D. Thomas, M.J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, A. Narechania, PANTHER: A library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003)CrossRefPubMedPubMedCentral P.D. Thomas, M.J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, A. Narechania, PANTHER: A library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat D.W. Huang, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44 (2008)CrossRef D.W. Huang, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44 (2008)CrossRef
18.
Zurück zum Zitat L.J. Jensen, M. Kuhn, M. Stark, S. Chaffron, C. Creevey, J. Muller, T. Doerks, P. Julien, A. Roth, M. Simonovic, P. Bork, STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37(suppl_1), D412–D416 (2008)PubMedPubMedCentral L.J. Jensen, M. Kuhn, M. Stark, S. Chaffron, C. Creevey, J. Muller, T. Doerks, P. Julien, A. Roth, M. Simonovic, P. Bork, STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37(suppl_1), D412–D416 (2008)PubMedPubMedCentral
19.
Zurück zum Zitat M. Seervi, J. Joseph, P.K. Sobhan, B.C. Bhavya, T.R. Santhoshkumar, Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models. Cell Death Dis. 2, e207 (2011)CrossRefPubMedPubMedCentral M. Seervi, J. Joseph, P.K. Sobhan, B.C. Bhavya, T.R. Santhoshkumar, Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models. Cell Death Dis. 2, e207 (2011)CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat J.C. Goldstein, C. Munoz-Pinedo, J.E. Ricci, S.R. Adams, A. Kelekar, M. Schuler, R.Y. Tsien, D.R. Green, Cytochrome c is released in a single step during apoptosis. Cell Death Differ. 12, 453–462 (2005)CrossRefPubMed J.C. Goldstein, C. Munoz-Pinedo, J.E. Ricci, S.R. Adams, A. Kelekar, M. Schuler, R.Y. Tsien, D.R. Green, Cytochrome c is released in a single step during apoptosis. Cell Death Differ. 12, 453–462 (2005)CrossRefPubMed
21.
Zurück zum Zitat N.V. Krakhmal, M.V. Zavyalova, E.V. Denisov, S.V. Vtorushin, V.M. Perelmuter, Cancer invasion: Patterns and mechanisms. Acta Nat. 7, 17–28 (2015)CrossRef N.V. Krakhmal, M.V. Zavyalova, E.V. Denisov, S.V. Vtorushin, V.M. Perelmuter, Cancer invasion: Patterns and mechanisms. Acta Nat. 7, 17–28 (2015)CrossRef
22.
Zurück zum Zitat T.M. Penning, J.E. Drury, Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 464, 241–250 (2007)CrossRefPubMedPubMedCentral T.M. Penning, J.E. Drury, Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 464, 241–250 (2007)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat C.Y. Chiang, C.C. Pan, H.Y. Chang, M.D. Lai, T.S. Tzai, Y.S. Tsai, P. Ling, H.S. Liu, B.F. Lee, H.L. Cheng, C.L. Ho, S.H. Chen, N.H. Chow, SH3BGRL3 protein as a potential prognostic biomarker for urothelial carcinoma: A novel binding partner of epidermal growth factor receptor. Clin. Cancer Res. 21, 5601–5611 (2015)CrossRefPubMed C.Y. Chiang, C.C. Pan, H.Y. Chang, M.D. Lai, T.S. Tzai, Y.S. Tsai, P. Ling, H.S. Liu, B.F. Lee, H.L. Cheng, C.L. Ho, S.H. Chen, N.H. Chow, SH3BGRL3 protein as a potential prognostic biomarker for urothelial carcinoma: A novel binding partner of epidermal growth factor receptor. Clin. Cancer Res. 21, 5601–5611 (2015)CrossRefPubMed
24.
Zurück zum Zitat E.S. Arnér, A. Holmgren, Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109 (2000)CrossRefPubMed E.S. Arnér, A. Holmgren, Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109 (2000)CrossRefPubMed
25.
Zurück zum Zitat J.J. Duan, J. Cai, Y.F. Guo, X.W. Bian, S.C. Yu, ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 139, 965–975 (2016)CrossRefPubMed J.J. Duan, J. Cai, Y.F. Guo, X.W. Bian, S.C. Yu, ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 139, 965–975 (2016)CrossRefPubMed
26.
Zurück zum Zitat M. Fukuda, S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, E. Nishida, CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308–311 (1997)CrossRefPubMed M. Fukuda, S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, E. Nishida, CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308–311 (1997)CrossRefPubMed
27.
Zurück zum Zitat K. Van Impe, T. Hubert, V. De Corte, B. Vanloo, C. Boucherie, J. Vandekerckhove, J. Gettemans, A new role for nuclear transport factor 2 and ran: Nuclear import of CapG. Traffic 9, 695–707 (2008)CrossRefPubMed K. Van Impe, T. Hubert, V. De Corte, B. Vanloo, C. Boucherie, J. Vandekerckhove, J. Gettemans, A new role for nuclear transport factor 2 and ran: Nuclear import of CapG. Traffic 9, 695–707 (2008)CrossRefPubMed
29.
Zurück zum Zitat M. Garg, D. Kanojia, A. Mayakonda, T.S. Ganesan, B. Sadhanandhan, S. Suresh, R.P. Nagare, J.W. Said, N.B. Doan, L.W. Ding, E. Baloglu, S. Shacham, M. Kauffman, H.P. Koeffler, Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci. Rep. 7(9749), 9749 (2017)CrossRefPubMedPubMedCentral M. Garg, D. Kanojia, A. Mayakonda, T.S. Ganesan, B. Sadhanandhan, S. Suresh, R.P. Nagare, J.W. Said, N.B. Doan, L.W. Ding, E. Baloglu, S. Shacham, M. Kauffman, H.P. Koeffler, Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci. Rep. 7(9749), 9749 (2017)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat J. Yang, M.A. Bill, G.S. Young, K. La Perle, Y. Landesman, S. Shacham, M. Kauffman, W. Senapedis, T. Kashyap, J.R. Saint-Martin, K. Kendra, G.B. Lesinski, Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One 9, e102983 (2014)CrossRefPubMedPubMedCentral J. Yang, M.A. Bill, G.S. Young, K. La Perle, Y. Landesman, S. Shacham, M. Kauffman, W. Senapedis, T. Kashyap, J.R. Saint-Martin, K. Kendra, G.B. Lesinski, Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One 9, e102983 (2014)CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat G. Sun, E. Guzman, V. Balasanyan, C.M. Conner, K. Wong, H.R. Zhou, K.S. Kosik, D.J. Montell, A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J. Cell Biol. 216, 3355–3368 (2017)CrossRefPubMedPubMedCentral G. Sun, E. Guzman, V. Balasanyan, C.M. Conner, K. Wong, H.R. Zhou, K.S. Kosik, D.J. Montell, A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J. Cell Biol. 216, 3355–3368 (2017)CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat S. Asthana, S. Chauhan, S. Labani, Breast and cervical cancer risk in India: An update. Indian J. Public Health 58, 5 (2014)CrossRefPubMed S. Asthana, S. Chauhan, S. Labani, Breast and cervical cancer risk in India: An update. Indian J. Public Health 58, 5 (2014)CrossRefPubMed
34.
Zurück zum Zitat X. Gào, B. Schöttker, Reduction–oxidation pathways involved in cancer development: A systematic review of literature reviews. Oncotarget 8(51888) (2017) X. Gào, B. Schöttker, Reduction–oxidation pathways involved in cancer development: A systematic review of literature reviews. Oncotarget 8(51888) (2017)
35.
Zurück zum Zitat A. Fernández-Medarde, E. Santos, Ras in cancer and developmental diseases. Genes & Cancer 2, 344–358 (2011)CrossRef A. Fernández-Medarde, E. Santos, Ras in cancer and developmental diseases. Genes & Cancer 2, 344–358 (2011)CrossRef
36.
Zurück zum Zitat M. El-Tanani, E.H. Dakir, B. Raynor, R. Morgan, Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers 8, E 35 (2016) M. El-Tanani, E.H. Dakir, B. Raynor, R. Morgan, Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers 8, E 35 (2016)
37.
Zurück zum Zitat G.L. Gravina, W. Senapedis, D. McCauley, E. Baloglu, S. Shacham, C. Festuccia, Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol. 7(85), 85 (2014)CrossRefPubMedPubMedCentral G.L. Gravina, W. Senapedis, D. McCauley, E. Baloglu, S. Shacham, C. Festuccia, Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol. 7(85), 85 (2014)CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Y.M. Chook, K.E. Süel, Nuclear import by karyopherin-βs: Recognition and inhibition. Biochim. Biophys. Acta 1813, 1593–1606 (2011)CrossRefPubMed Y.M. Chook, K.E. Süel, Nuclear import by karyopherin-βs: Recognition and inhibition. Biochim. Biophys. Acta 1813, 1593–1606 (2011)CrossRefPubMed
39.
Zurück zum Zitat S.C. Mutka, W.Q. Yang, S.D. Dong, S.L. Ward, D.A. Craig, P.B. Timmermans, S. Murli, Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69, 510–517 (2009)CrossRefPubMedPubMedCentral S.C. Mutka, W.Q. Yang, S.D. Dong, S.L. Ward, D.A. Craig, P.B. Timmermans, S. Murli, Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69, 510–517 (2009)CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Y. Chen, S.C. Camacho, T.R. Silvers, A.R. Razak, N.Y. Gabrail, J.F. Gerecitano, E. Kalir, E. Pereira, B.R. Evans, S.J. Ramus, F. Huang, N. Priedigkeit, E. Rordriguez, M. Donovan, F. Khan, T. Kalir, R. Sebra, A. Uzilov, R. Chen, R. Sinha, R. Hm, J.N. Alpert, S. Billaud, D. Shacham, Y. McCauley, T. Landesman, M. Rashal, M.R. Kauffman, M. mirza, P. Mau-Sørensen, J. Dottino, A. Martignetti, Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin. Cancer Res. 23, 1552–1563 (2017)CrossRefPubMed Y. Chen, S.C. Camacho, T.R. Silvers, A.R. Razak, N.Y. Gabrail, J.F. Gerecitano, E. Kalir, E. Pereira, B.R. Evans, S.J. Ramus, F. Huang, N. Priedigkeit, E. Rordriguez, M. Donovan, F. Khan, T. Kalir, R. Sebra, A. Uzilov, R. Chen, R. Sinha, R. Hm, J.N. Alpert, S. Billaud, D. Shacham, Y. McCauley, T. Landesman, M. Rashal, M.R. Kauffman, M. mirza, P. Mau-Sørensen, J. Dottino, A. Martignetti, Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin. Cancer Res. 23, 1552–1563 (2017)CrossRefPubMed
41.
Zurück zum Zitat A.S. Azmi, Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr. Cancer Drug Targets 13, 906–914 (2013)CrossRefPubMed A.S. Azmi, Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr. Cancer Drug Targets 13, 906–914 (2013)CrossRefPubMed
42.
43.
Zurück zum Zitat C. Ginestier, M.H. Hur, E. Charafe-Jauffre, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007)CrossRefPubMedPubMedCentral C. Ginestier, M.H. Hur, E. Charafe-Jauffre, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007)CrossRefPubMedPubMedCentral
Metadaten
Titel
Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway
verfasst von
Mahendra Seervi
S. Sumi
Aneesh Chandrasekharan
Abhay K. Sharma
T. R. SanthoshKumar
Publikationsdatum
30.05.2019
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 5/2019
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00451-1

Weitere Artikel der Ausgabe 5/2019

Cellular Oncology 5/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …